Research Topics
| Peter LindgrenSummaryAffiliation: Stockholm Health Economics Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and AustraliaPeter Lindgren
Stockholm Health Economics Consulting, Uppsala, Sweden
Pharmacoeconomics 20:101-8. 2002..To investigate the cost effectiveness of exemestane compared to megestrol in post-menopausal women after tamoxifen failure...
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatinPeter Lindgren
European Health Economics, Vasagatan 38, 111 20 Stockholm, Sweden
Eur Heart J 28:1448-53. 2007....
Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effectivePeter Lindgren
Karolinska Institutet, Stockholm, Sweden
Int J Technol Assess Health Care 23:177-83. 2007..As such, a program is demanding in terms of resources; it is necessary to assess whether it would be money well spent. This determination was the purpose of this study...
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugsP Lindgren
European Health Economics, Stockholm, Sweden
Int J Clin Pract 61:1410-4. 2007..Less than half of patients in Scandinavian societies achieve target cholesterol values established by consensus coronary prevention panels...
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimenP Lindgren
i3innovus, Vasagatan 38, 11120 Stockholm, Sweden
Heart 94:e4. 2008..To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden...
Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudyPeter Lindgren
European Health Economics, Vasagatan 38, 111 20 Stockholm, Sweden
Eur J Health Econ 8:25-30. 2007..These results are helpful in future economic evaluations of primary preventive measures in cardiovascular medicine...
Utility loss and indirect costs after stroke in SwedenPeter Lindgren
i3 Innovus bInstitute of Environmental Medicine, Karolinska Institute, Sweden
Eur J Cardiovasc Prev Rehabil 15:230-3. 2008..The purpose of the study was to assess the utility loss and indirect costs following a stroke in Sweden...
Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practicePeter Lindgren
Stockholm Health Economics, Stockholm, Sweden
Eur J Cardiovasc Prev Rehabil 12:530-4. 2005..Our goal was to investigate if this translates to a higher risk of cardiovascular events in real clinical practice...
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1Peter Lindgren
i3 Innovus, Stockholm, Sweden
Pharmacoeconomics 27:221-30. 2009....
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trialsJenny Berg
European Health Economics, Stockholm, Sweden
Clin Ther 29:1184-202. 2007..Several health economic studies have shown that the use of clopidogrel is cost-effective to prevent ischemic events in non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina...
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trialAnna Ringborg
Stockholm Health Economics, Stockholm, Sweden
Eur J Health Econ 6:354-6, 358-62. 2005..Thus the predicted cost-effectiveness ratio of long-term treatment with clopidogrel in patients undergoing PCI is well below the threshold values currently considered cost-effective...
From 4S to IDEAL: the health economics of the statin trialsPeter Lindgren
i3 Innovus, Stockholm, Sweden
Eur J Cardiovasc Prev Rehabil 16:138-43. 2009..New therapies entering the field must now compare favourably with statin therapy, whereas earlier a comparison versus placebo would have been sufficient to demonstrate cost effectiveness...
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)Peter Lindgren
Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
Eur J Cardiovasc Prev Rehabil 12:29-36. 2005..CONCLUSION: Based on comparisons with the WOSCOPS and 4S studies, atorvastatin at 10 mg to treat patients as in the ASCOT study, appears to be a cost-effective strategy...
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trialP Lindgren
Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
J Intern Med 255:562-70. 2004..The purpose of this study was to evaluate the long-term cost-effectiveness of clopidogrel on top of standard therapy (including ASA) in patients with acute coronary syndromes without ST-segment elevation in Sweden...
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in SwedenAnna Ringborg
i3 Innovus, Karolinska Institute, Stockholm, Sweden
Eur J Cardiovasc Prev Rehabil 16:576-82. 2009..The aim of this study was to determine the health care costs associated with acute myocardial infarction (AMI) and stroke in patients with type 2 diabetes in Sweden...
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritisG Kobelt
Karolinska Institute, Stockholm, Sweden
Rheumatology (Oxford) 44:1169-75. 2005..The objective of this study was to improve the model by incorporating the effect of a subjective measure of disease severity and activity (global VAS)...
Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trialsJenny Berg
i3 Innovus, Stockholm, Sweden
Curr Med Res Opin 24:2089-101. 2008..This analysis adds to existing knowledge by providing further data on the cost-effectiveness of clopidogrel in PCI across a wide spectrum of patients...
Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm--a stochastic model of exercise and dietary advicePeter Lindgren
Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Prev Med 36:403-9. 2003..Primary prevention may be a way to lower the risk burden of coronary heart disease, but we must establish that preventive programs are cost-effective...
Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in GermanyJenny Berg
i3 Innovus, Vasagatan 38, SE 111 20 Stockholm, Sweden
Respir Med 102:219-31. 2008..The objective of this study was to assess the cost-effectiveness of FE(NO) measurement at a reimbursement price of euro34 using NIOX MINO, a portable non-invasive FE(NO) monitor, in asthma diagnosis and management...
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in SwedenPeter Lindgren
Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
Clin Ther 27:100-10. 2005..In addition, a within-trial cost-effectiveness analysis showed favorable costs per event avoided. However, to estimate the long-term effects, a modeling approach is necessary...
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillationAnna Ringborg
Europace 10:403-11. 2008..To estimate costs of admission and costs incurred on an annual basis by patients with atrial fibrillation (AF) in Greece, Italy, Poland, Spain, and the Netherlands...
Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register dataA Ringborg
i3 Innovus, Stockholm, Sweden
Int J Clin Pract 62:708-16. 2008..To examine medical resource use of Swedish patients with type 2 diabetes during 2000-2004 and to estimate annual costs of care...
Costs and quality of life of multiple sclerosis in SwedenJenny Berg
Stockholm Health Economics, Stockholm, Sweden
Eur J Health Econ 7:S75-85. 2006..Compared to an earlier cost study in 1998 that included a similar sample, and adjusting for differential timing and estimated national use of DMDs, costs have increased by approximately 5% between 1998 and 2005...
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS)A Ringborg
i3 Innovus, Stockholm, Sweden
Int J Clin Pract 63:997-1007. 2009..To estimate diabetes-related resource use and investigate its predictors among individuals with type 2 diabetes in 24 countries in Asia, Latin America, the Middle East and Africa...
Factors determining utility measured with the EQ-5D in patients with atrial fibrillationJenny Berg
Institute of Environmental Medicine, Karolinska Institute, Solna, Sweden
Qual Life Res 19:381-90. 2010..The objective was to analyse the factors determining utility in patients with all types of AF, both at baseline and after 1 year from inclusion, based on data from the Euro heart survey...
Economic evidence in Parkinson's disease: a reviewPeter Lindgren
Department of Cardiovascular Epidemiology, Institute of Environmentel Medicine Karolinska Institutet, Stockholm, Sweden
Eur J Health Econ 5:S63-6. 2004
Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based studyA Ringborg
i3 Innovus, Karolinska Institute, Stockholm, Sweden
Diabet Med 25:1178-86. 2008..To determine the prevalence and incidence of Type 2 diabetes and its complications in Uppsala county, Sweden between 1996 and 2003...
Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetesA Ringborg
i3 Innovus, Stockholm, Sweden
Diabetes Metab 36:198-203. 2010....
Cost of Parkinson's disease in EuropeP Lindgren
Stockholm Health Economics, Stockholm, Sweden and Department of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden
Eur J Neurol 12:68-73. 2005
Increased incidence of malignancies in Sweden after the Chernobyl accident--a promoting effect?Martin Tondel
Department of Molecular and Clinical Medicine, Division of Occupational and Environmental Medicine, Linkoping University, Linkoping SE 581 85, Sweden
Am J Ind Med 49:159-68. 2006..After the Chernobyl accident in 1986, as much as 5% of the released caesium-137 was deposited in Sweden due to a heavy rainfall 2 days after the event. A study of increased incidence of malignancies was initiated after the accident...
Costs and quality of life of multiple sclerosis in ItalyGisela Kobelt
Lund University, Lund, Sweden
Eur J Health Econ 7:S45-54. 2006..3 quality-adjusted life year (QALY) per patient. Relapses for patients with an EDSS score of <5 are associated with a cost of approximately euro 4000 and a utility loss of 0.18 during the quarter in which they occur...
Costs and quality of life of multiple sclerosis in GermanyGisela Kobelt
Lund University, Lund, Sweden
Eur J Health Econ 7:S34-44. 2006..This is most likely due to a difference in the severity distribution of the two samples and to changes in health-care consumption overall in the country, such as the introduction of diagnosis-related groups (DRGs, Fallpauschalen)...
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE studyAndre Lamy
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
Eur J Cardiovasc Prev Rehabil 11:460-5. 2004..The CURE study demonstrated that clopidogrel prevents a range of ischaemic cardiovascular events in patients with Acute Coronary Syndromes (unstable angina or non-ST-segment elevation MI)...
Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritisGisela Kobelt
Health Dynamics International, Speracedes, France
Arthritis Rheum 46:2310-9. 2002..Two simulation models were developed to analyze the cost-effectiveness of new treatments that affect the progression of rheumatoid arthritis (RA)...
Costs and quality of life of multiple sclerosis in SwitzerlandGisela Kobelt
Lund University, Lund, Sweden
Eur J Health Econ 7:S86-95. 2006..Despite this, a large amount of costs falls on families providing care, in particular for patients with severe disease...
Costs and quality of life of multiple sclerosis in AustriaGisela Kobelt
Lund University, Lund, Sweden
Eur J Health Econ 7:S14-23. 2006..This loss increases to approximately 0.4 for patients over 60 years of age with an average EDSS score of 6.0-6.5. Patients with a recent relapse had lower utility (-0.1) and higher costs (+ euro 4.750)...
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysisGisela Kobelt
Lund University, Lund, Sweden
Eur J Health Econ 7:S5-13. 2006..This paper describes the methodology used for the study, while results are presented in the individual country reports...
